Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter randomized controlled non-inferiority study (RIFREE)
This study, called RIFREE, is looking for a better way to treat a very serious heart infection called staphylococcal prosthetic valve endocarditis. This infection happens when bacteria, often staphylococcus, infect an artificial heart valve. Doctors are testing two treatment plans: one that includes a medicine called rifampin, and another that doesn't. They want to see if the rifampin-free plan is just as effective at saving lives as the current standard treatment that includes rifampin. The main thing they'll measure is how many people are still alive six months after starting treatment. They will also look at how quickly people recover, any side effects, and if the infection comes back. This research aims to find safer and more effective ways to treat this life-threatening condition.
At a glance
What is this study about?
This study is called RIFREE, and it's looking into a serious heart infection that can affect people who have had artificial heart valves fitted. This infection is called staphylococcal prosthetic valve endocarditis. It happens when specific bacteria, often called 'staph' bacteria, get into the bloodstream and settle on the artificial valve, causing a dangerous infection.
Currently, there are different ways to treat this infection, often involving strong antibiotics. One of the medicines sometimes used is called rifampin. This study wants to find out if a treatment plan that doesn't include rifampin is just as effective as one that does. The main goal is to see if patients treated without rifampin have the same survival rates after six months as those who receive rifampin. This is important because finding effective treatments with fewer side effects or complications is always a medical priority.
By comparing these two treatment approaches, researchers hope to improve how this severe infection is managed. They'll also be closely monitoring other key things like whether the infection comes back, if patients need further surgery, how long they stay in hospital, and if any side effects occur. This detailed look will help doctors decide the best way to treat this condition in the future.
Key takeaways
- The study compares two ways to treat a serious heart infection on artificial valves.
- It aims to see if a treatment without rifampin is as effective as one with it.
- The main measure is patient survival after six months.
- Researchers will also look at safety, side effects, and re-infection.
- Participation involves receiving one of the study treatments and regular check-ups for up to a year.
- The goal is to find safer and better treatments for this infection.
Who may be eligible?
To join this study, you must be at least 18 years old. Both men and women can take part. You also need to have recently been diagnosed with a specific heart infection on an artificial heart valve, caused by staphylococcus bacteria. The medical team will check your full health history to make sure the study is a safe and suitable option for you.
There might be other health conditions or medicines you're taking that would mean you can't join. This is to ensure your safety and that the study results are clear. For example, if you have certain kidney or liver problems, or are allergic to study medicines, you might not be able to participate. Your doctors will discuss all these details with you carefully.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I 18 years old or older?
- Do I have a staphylococcal infection on an artificial heart valve?
- Am I able to commit to regular follow-up appointments for up to 12 months?
- Do I understand that there are different treatment groups I could be in?
- Have I discussed all my current medications and health conditions with my doctor?
What does participation involve?
If you decide to take part in this study, you'll be randomly assigned to one of two treatment groups – like flipping a coin. One group will receive a treatment plan that includes rifampin, and the other will receive a plan without it. Both plans involve various antibiotics given as infusions into a vein or as tablets.
You'll be carefully monitored throughout your treatment and for a period afterwards. This will involve regular doctor's appointments, blood tests, and other checks to see how you're responding to the treatment, if the infection is clearing up, and to look for any side effects. These check-ups will continue for up to 12 months after you've started the study. The total duration of your participation in the study, including follow-up, will be around 12 months.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is staphylococcal prosthetic valve endocarditis?
It's a serious infection of an artificial heart valve caused by bacteria, often called 'staph' bacteria.
What is rifampin?
Rifampin is a type of antibiotic medication. This study is comparing treatments with and without it.
Will I know if I'm getting rifampin or not?
No, you will be randomly assigned to a group, and to keep the study fair, you won't know which group you're in until after the study is complete, unless medically necessary.
How long will I be in the study?
The study involves treatment and follow-up for up to 12 months.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time without having to give a reason, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.